Low-Dose Naltrexone in a 17-Year-Old Adolescent
Low-dose naltrexone (LDN) is not FDA-approved for pediatric use and lacks robust evidence in adolescents; however, if considering off-label use after exhausting standard therapies, start with 0.1 mg/kg (approximately 4.5 mg for average weight) once daily, monitor liver function tests at baseline and monthly for 3 months, and ensure the patient is opioid-free for at least 7-10 days before initiation.
Critical Context: FDA-Approved vs. Off-Label Use
The FDA-approved naltrexone dosing is 50 mg daily for opioid use disorder (approved for ages 16+) and alcohol use disorder 1. However, your question specifically asks about "low-dose" naltrexone, which refers to off-label dosing at 0.5-6 mg daily—a completely different therapeutic paradigm not addressed in FDA labeling or major pediatric guidelines.
What the Guidelines Actually Say
The American Academy of Pediatrics (2016) discusses naltrexone for adolescent opioid use disorder but only at standard 50 mg doses, noting it "has proven to be an effective treatment" with "very limited potential for misuse or diversion" and may be particularly useful for adolescents with co-occurring alcohol use disorder 2. The CDC guideline similarly addresses only standard-dose naltrexone (50 mg) for opioid use disorder 3.
Neither guideline addresses low-dose naltrexone for other indications.
Off-Label Low-Dose Naltrexone: The Evidence Gap
Pediatric Safety Data
The only pediatric study of LDN examined 0.1 mg/kg daily in children with Crohn's disease (mean age 12.3 years, range 8-17) 4. This dose was:
- Well tolerated without serious adverse events over 16 weeks
- Generally equivalent to 3-6 mg daily depending on weight
- Associated with improved disease activity and quality of life
A review of naltrexone in autistic children found doses of 0.5-2 mg/kg/day (substantially higher than typical LDN) were used, with transient sedation as the most common side effect 5.
Adult LDN Evidence
Recent systematic reviews reveal the fundamental problem: early positive findings from uncontrolled studies were rarely replicated in placebo-controlled trials 6. A 2026 narrative review concluded that "current evidence does not support routine clinical use" and that LDN "may have a pragmatic role in treatment-resistant cases where standard therapies have failed" 6.
Practical Dosing Algorithm (If Proceeding Off-Label)
Pre-Treatment Requirements
- Verify opioid-free status: Minimum 7-10 days for short-acting opioids; up to 2 weeks for buprenorphine/methadone 1
- Baseline liver function tests: Naltrexone carries hepatotoxicity risk, particularly at doses >50 mg, but monitoring is prudent even at low doses 1
- Urine drug screen: Confirm absence of opioids 1
- Consider naloxone challenge test if any doubt about opioid use (see FDA protocol below)
Dosing Strategy
Start: 0.1 mg/kg once daily (typically 4.5 mg for a 45 kg adolescent) 4
- This is the only pediatric-studied dose
- Adult LDN typically uses 4.5 mg daily 6, 7
- Recent evidence suggests effective doses are "idiosyncratic" and may require titration from 0.1-4.5 mg 8
Titration: If no response after 4 weeks, consider increasing by 0.5-1 mg increments every 2-4 weeks up to maximum 6 mg daily 6, 7
Timing: Evening dosing may reduce daytime sedation if it occurs
Monitoring Protocol
- Liver function tests: Baseline, then monthly for 3 months, then every 3 months 1
- Clinical response: Assess at 4,8, and 12 weeks using validated outcome measures specific to the condition being treated
- Adverse effects: Monitor for vivid dreams, drowsiness, dizziness, nausea (most common) 9
Duration
The Crohn's study used 16 weeks 4. Adult chronic pain studies typically evaluate 8-12 weeks 9, 10. Reassess benefit-risk at 12 weeks minimum before continuing long-term.
Critical Safety Considerations
Hepatotoxicity Warning
The FDA label explicitly warns: "There may be a higher risk of hepatocellular injury with single doses above 50 mg" 1. While LDN uses much lower doses, baseline and ongoing liver monitoring remains essential given the drug class effect.
Loss of Opioid Tolerance
This is life-threatening: Naltrexone blocks opioid receptors. If the patient requires emergency opioid analgesia (trauma, surgery), they will need higher doses and may not respond predictably 1. The patient and family must carry a medical alert card stating they are on naltrexone.
Precipitated Withdrawal Risk
Even at low doses, initiating naltrexone in someone with occult opioid use can precipitate severe withdrawal 1. The 7-10 day opioid-free period is non-negotiable.
When NOT to Use LDN
- Active opioid use or dependence (use standard 50 mg dose per guidelines if treating opioid use disorder) 2
- Acute hepatitis or liver failure 1
- Anticipated need for opioid analgesia
- Patient/family unable to understand risks or comply with monitoring
The Bottom Line on Evidence Quality
A 2026 systematic review states plainly: "Most available evidence consists of case reports and small feasibility studies that are prone to publication bias and rely heavily on subjective outcomes" 6. The single pediatric RCT had only 14 subjects 4. You are prescribing based on extremely limited evidence.
Informed Consent Must Include:
- LDN is not FDA-approved for this indication or age group
- Evidence is preliminary and contradictory
- Standard therapies should be exhausted first
- This is an experimental approach with uncertain benefit
- Monitoring requirements and safety risks
Alternative Consideration
If the indication is opioid use disorder, use FDA-approved standard-dose naltrexone (50 mg) or preferably buprenorphine, which has stronger evidence in adolescents 2. The AAP explicitly recommends buprenorphine as first-line for adolescent opioid use disorder, noting it is FDA-approved for ages 16+ with demonstrated safety and efficacy 2.